Codexis Achieves Schering-Plough Milestone

Codexis, Inc. has achieved a significant development milestone under a research agreement with Schering-Plough to rapidly generate a novel biocatalytic process to produce a key intermediate for an undisclosed human therapeutics compound. This program is based on Codexis’ MolecularBreeding pharmaceutical process re-engineering platform, and is expected to reduce manufacturing costs and environmental waste in the final production process.

“The agreement with Schering-Plough was announced in March, and Codexis has quickly met the initial development milestone,” said Alan Shaw, Ph.D., Codexis president and chief executive officer. “We are very pleased with this substantial progress in our collaboration and look forward to continuing to demonstrate the value of our technology to this important partner. An increasing number of worldwide pharmaceutical partners are recognizing the Codexis competitive advantage in developing rapid, efficient clinical-scale manufacturing production processes.”